Abivax : KOL call reassuring
>Confirmation of the potential of obefazimod in UC - Yesterday after market close, Abivax organised a digital conference in the presence of Dr Marla Dubinsky (Icahn School of Medicine), Dr Parambir Dulai (Northwestern University) and the group’s management in order to expose the medical need and potential harboured by obefazimod in ulcerative colitis (UC). Key takeaways:2-3 million patients in the US suffer from inflammatory diseases of the intestines with 60% af...ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of novel anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.